Potential Benefits of Pre-emptive PGx Testing in Male Breast Cancer Patients
The objective is to report a case of recurrent breast cancer in a poor CYP2D6 metabolizer male patient on tamoxifen, and how pharmacogenomic (PGx) testing can play an important role in selecting appropriate adjuvant endocrine therapy. The case examined here is a 60-year-old white male diagnosed w...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
University of Minnesota Libraries Publishing
2019-12-01
|
| Series: | INNOVATIONS in Pharmacy |
| Subjects: | |
| Online Access: | https://pubs.lib.umn.edu/index.php/innovations/article/view/2303 |
| _version_ | 1828494588896083968 |
|---|---|
| author | Heather Randles Nina Abraham Michael J. Schuh |
| author_facet | Heather Randles Nina Abraham Michael J. Schuh |
| author_sort | Heather Randles |
| collection | DOAJ |
| description | The objective is to report a case of recurrent breast cancer in a poor CYP2D6 metabolizer male patient on tamoxifen, and how pharmacogenomic (PGx) testing can play an important role in selecting appropriate adjuvant endocrine therapy.
The case examined here is a 60-year-old white male diagnosed with recurrence of breast cancer. The patient was prescribed tamoxifen four years prior as adjuvant endocrine therapy after initial treatment with surgery. PGx testing ordered at the time of recurrence revealed patient is a poor metabolizer of CYP2D6, which may decrease the efficacy of tamoxifen. The results prompted a change in therapy to an aromatase inhibitor (AI).
This case illustrates the potential benefits of preemptive PGx testing in a male breast cancer patient to assist in selecting appropriate adjuvant therapy based on how the patient metabolizes medications. In addition, PGx testing encourages patient involvement by emphasizing the association of genetics in determining treatment. The ultimate goal in performing these tests is to individualize treatment to improve safety and efficacy while minimizing adverse drug reactions.
Article Type: Case Study |
| first_indexed | 2024-12-11T11:58:42Z |
| format | Article |
| id | doaj.art-b788ee50a60c4c119509a4bbe5edc28a |
| institution | Directory Open Access Journal |
| issn | 2155-0417 |
| language | English |
| last_indexed | 2024-12-11T11:58:42Z |
| publishDate | 2019-12-01 |
| publisher | University of Minnesota Libraries Publishing |
| record_format | Article |
| series | INNOVATIONS in Pharmacy |
| spelling | doaj.art-b788ee50a60c4c119509a4bbe5edc28a2022-12-22T01:08:07ZengUniversity of Minnesota Libraries PublishingINNOVATIONS in Pharmacy2155-04172019-12-0110410.24926/iip.v10i4.2303Potential Benefits of Pre-emptive PGx Testing in Male Breast Cancer PatientsHeather Randles0Nina Abraham1Michael J. Schuh2Mayo Clinic Department of PharmacyPalm Beach Atlantic University-Lloyd L. Gregory School of PharmacyMayo Clinic Department of PharmacyThe objective is to report a case of recurrent breast cancer in a poor CYP2D6 metabolizer male patient on tamoxifen, and how pharmacogenomic (PGx) testing can play an important role in selecting appropriate adjuvant endocrine therapy. The case examined here is a 60-year-old white male diagnosed with recurrence of breast cancer. The patient was prescribed tamoxifen four years prior as adjuvant endocrine therapy after initial treatment with surgery. PGx testing ordered at the time of recurrence revealed patient is a poor metabolizer of CYP2D6, which may decrease the efficacy of tamoxifen. The results prompted a change in therapy to an aromatase inhibitor (AI). This case illustrates the potential benefits of preemptive PGx testing in a male breast cancer patient to assist in selecting appropriate adjuvant therapy based on how the patient metabolizes medications. In addition, PGx testing encourages patient involvement by emphasizing the association of genetics in determining treatment. The ultimate goal in performing these tests is to individualize treatment to improve safety and efficacy while minimizing adverse drug reactions. Article Type: Case Studyhttps://pubs.lib.umn.edu/index.php/innovations/article/view/2303CYP2D6, male breast cancer, pharmacogenomic, PGx testing, tamoxifen |
| spellingShingle | Heather Randles Nina Abraham Michael J. Schuh Potential Benefits of Pre-emptive PGx Testing in Male Breast Cancer Patients INNOVATIONS in Pharmacy CYP2D6, male breast cancer, pharmacogenomic, PGx testing, tamoxifen |
| title | Potential Benefits of Pre-emptive PGx Testing in Male Breast Cancer Patients |
| title_full | Potential Benefits of Pre-emptive PGx Testing in Male Breast Cancer Patients |
| title_fullStr | Potential Benefits of Pre-emptive PGx Testing in Male Breast Cancer Patients |
| title_full_unstemmed | Potential Benefits of Pre-emptive PGx Testing in Male Breast Cancer Patients |
| title_short | Potential Benefits of Pre-emptive PGx Testing in Male Breast Cancer Patients |
| title_sort | potential benefits of pre emptive pgx testing in male breast cancer patients |
| topic | CYP2D6, male breast cancer, pharmacogenomic, PGx testing, tamoxifen |
| url | https://pubs.lib.umn.edu/index.php/innovations/article/view/2303 |
| work_keys_str_mv | AT heatherrandles potentialbenefitsofpreemptivepgxtestinginmalebreastcancerpatients AT ninaabraham potentialbenefitsofpreemptivepgxtestinginmalebreastcancerpatients AT michaeljschuh potentialbenefitsofpreemptivepgxtestinginmalebreastcancerpatients |